Maryann Redlinger

1.8k total citations · 1 hit paper
25 papers, 1.1k citations indexed

About

Maryann Redlinger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maryann Redlinger has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maryann Redlinger's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Maryann Redlinger is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Maryann Redlinger collaborates with scholars based in United States, United Kingdom and China. Maryann Redlinger's co-authors include Peter J. O’Dwyer, Keith T. Flaherty, Marcia S. Brose, Andrea B. Troxel, Laurie A. Loevner, Kanchan Puttaswamy, Anoma Nellore, Susan J. Mandel, Vandana G. Abramson and Lynn M. Schuchter and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Maryann Redlinger

25 papers receiving 1.1k citations

Hit Papers

Phase II Trial of Sorafenib in Advanced Thyroid Cancer 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of Sorafenib in Advanced Thyroid Cancer
    2008 535 citations Vandana G. Abramson, Andrea B. Troxel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maryann Redlinger United States 14 525 459 453 193 167 25 1.1k
Suresh Anaganti Italy 9 395 0.8× 343 0.7× 301 0.7× 169 0.9× 103 0.6× 10 814
Jessica Read United Kingdom 9 733 1.4× 428 0.9× 762 1.7× 514 2.7× 247 1.5× 11 1.6k
John Frye United States 10 286 0.5× 222 0.5× 230 0.5× 172 0.9× 100 0.6× 24 754
Hitoyasu Futami Japan 16 420 0.8× 330 0.7× 216 0.5× 115 0.6× 246 1.5× 41 869
Małgorzata Oczko‐Wojciechowska Poland 21 265 0.5× 690 1.5× 723 1.6× 210 1.1× 81 0.5× 61 1.4k
Jaume Capdevila Spain 18 277 0.5× 150 0.3× 758 1.7× 158 0.8× 94 0.6× 41 1.0k
Teresa Di Desidero Italy 24 542 1.0× 421 0.9× 203 0.4× 253 1.3× 32 0.2× 52 1.1k
Helen Musgrove United Kingdom 6 415 0.8× 441 1.0× 110 0.2× 289 1.5× 39 0.2× 7 852
Alessandra Spitale Switzerland 11 608 1.2× 187 0.4× 791 1.7× 236 1.2× 116 0.7× 22 1.5k
Agnieszka Czarniecka Poland 19 221 0.4× 462 1.0× 1.0k 2.3× 141 0.7× 84 0.5× 69 1.5k

Countries citing papers authored by Maryann Redlinger

Since Specialization
Citations

This map shows the geographic impact of Maryann Redlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maryann Redlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maryann Redlinger more than expected).

Fields of papers citing papers by Maryann Redlinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maryann Redlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maryann Redlinger. The network helps show where Maryann Redlinger may publish in the future.

Co-authorship network of co-authors of Maryann Redlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Maryann Redlinger. A scholar is included among the top collaborators of Maryann Redlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maryann Redlinger. Maryann Redlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Haas, Naomi B., Leonard J. Appleman, Mark N. Stein, et al.. (2019). Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research. 25(7). 2080–2087. 112 indexed citations
2.
O’Hara, Mark H., Thomas B. Karasic, Irina A. Vasilevskaya, et al.. (2017). Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.. Journal of Clinical Oncology. 35(15_suppl). 3545–3545. 24 indexed citations
3.
Ciunci, Christine, Rodolfo F. Perini, Anjali Narayan Avadhani, et al.. (2013). Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 120(1). 77–85. 21 indexed citations
4.
Flaherty, Keith T., Chetan Lathia, Reginald F. Frye, et al.. (2011). Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemotherapy and Pharmacology. 68(5). 1111–1118. 43 indexed citations
5.
Algazy, Kenneth M., Lynn M. Schuchter, Angela DeMichele, et al.. (2011). Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors. Cancer Research. 71(8_Supplement). 4500–4500. 2 indexed citations
6.
Denlinger, Crystal S., Rebecca Blanchard, Lu Xu, et al.. (2009). Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65(1). 97–105. 21 indexed citations
7.
Brose, Marcia S., Andrea B. Troxel, Maryann Redlinger, et al.. (2009). Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. Journal of Clinical Oncology. 27(15_suppl). 6002–6002. 27 indexed citations
8.
Abramson, Vandana G., Andrea B. Troxel, Anoma Nellore, et al.. (2008). Phase II Trial of Sorafenib in Advanced Thyroid Cancer. Journal of Clinical Oncology. 26(29). 4714–4719. 535 indexed citations breakdown →
9.
Flaherty, Keith T., Joan H. Schiller, Lynn M. Schuchter, et al.. (2008). A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clinical Cancer Research. 14(15). 4836–4842. 118 indexed citations
10.
Brose, Marcia S., Anoma Nellore, Maryann Redlinger, et al.. (2008). A phase II study of sorafenib in metastatic thyroid carcinoma. Journal of Clinical Oncology. 26(15_suppl). 6026–6026. 4 indexed citations
11.
Puttaswamy, Kanchan, Wiem Lassoued, Maryann Redlinger, et al.. (2007). Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. Journal of Clinical Oncology. 25(18_suppl). 6019–6019. 13 indexed citations
12.
Schiller, Joan H., et al.. (2006). Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. Journal of Clinical Oncology. 24(18_suppl). 7194–7194. 42 indexed citations
13.
Flaherty, Keith T., et al.. (2004). A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemotherapy and Pharmacology. 53(5). 404–408. 12 indexed citations
14.
Veronese, M L, James Stevenson, Weijing Sun, et al.. (2004). Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. European Journal of Cancer. 40(4). 508–514. 14 indexed citations
15.
Redlinger, Maryann, Amy Kramer, Keith T. Flaherty, et al.. (2004). A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. Journal of Clinical Oncology. 22(14_suppl). 3767–3767. 10 indexed citations
16.
Flaherty, Keith T., James Stevenson, Stephen M. Hahn, Maryann Redlinger, & Peter J. O’Dwyer. (2003). Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology. 52(3). 217–222. 1 indexed citations
17.
Sun, Weijing, James Stevenson, James M. Gallo, et al.. (2002). Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.. PubMed. 8(10). 3100–4. 14 indexed citations
18.
Stevenson, James, Maryann Redlinger, Wenguang Sun, et al.. (2001). Pharmacokinetic (PK)/pharmacodynamic (PD) trial of the new generation platinum compound ZD0473 administered as an iv infusion every 21 days. European Journal of Cancer. 37. S72–S72. 1 indexed citations
19.
Stevenson, James, Maryann Redlinger, Leo A. J. Kluijtmans, et al.. (2001). Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer. Journal of Clinical Oncology. 19(20). 4081–4087. 36 indexed citations
20.
Stevenson, James, Maryann Redlinger, Weijing Sun, Daniel G. Haller, & Peter J. O’Dwyer. (2000). Irinotecan and UFT/leucovorin in patients with advanced cancers.. PubMed. 14(10 Suppl 9). 91–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suresh Anaganti Breakdown of academic impact, for papers by Jessica Read Breakdown of academic impact, for papers by John Frye Breakdown of academic impact, for papers by Hitoyasu Futami Breakdown of academic impact, for papers by Małgorzata Oczko‐Wojciechowska Breakdown of academic impact, for papers by Jaume Capdevila Breakdown of academic impact, for papers by Teresa Di Desidero Breakdown of academic impact, for papers by Helen Musgrove Breakdown of academic impact, for papers by Alessandra Spitale Breakdown of academic impact, for papers by Agnieszka Czarniecka
Rankless by CCL
2026